期刊文献+

子宫内膜样腺癌组织中TFF3、ER、PR的表达及意义 被引量:6

下载PDF
导出
摘要 目的探讨子宫内膜样腺癌(EC)组织中三叶因子3(TFF3)、雌激素受体(ER)及孕激素受体(PR)的表达及意义。方法采用免疫组化SP法检测15例良性子宫肌瘤组织、20例子宫内膜不典型增生组织、42例EC组织中的TFF3、ER和PR,分析TFF3、ER、PR表达与EC临床病理参数的关系及其相关性。结果 TFF3在良性子宫肌瘤组织中的阳性表达率为20.0%,不典型增生组织中为45.0%,EC组织中为66.7%,不同组织间比较P均<0.01;TFF3蛋白表达与EC的组织学分级和病理分期有关(P均<0.05),与浸润程度和淋巴结转移无关。ER在良性子宫肌瘤组织中的阳性表达率为93.3%,不典型增生组织中为70.0%,EC组织中为54.8%,不同组织间比较P均<0.05;ER阳性表达与EC的组织学分级相关(P<0.05),与分期、淋巴结转移和浸润程度无关。PR在良性子宫肌瘤组织中阳性表达率为86.7%,不典型增生组织中为75.0%,EC组织中为59.5%,不同组织间比较P>0.05;PR表达与EC的组织学分级相关(P<0.05),与分期、淋巴结转移和浸润程度无关。EC组织中TFF3表达与ER、PR均呈正相关(r=0.002、0.004,P均<0.01)。结论 EC组织中TFF3表达明显升高,ER表达明显下降;TFF3、ER、PR对EC的发生、发展及预后可能起重要作用。
出处 《山东医药》 CAS 2014年第12期35-37,F0003,共4页 Shandong Medical Journal
  • 相关文献

参考文献15

  • 1Bansal N, Yendluri V, Wenham RM. The molecular biology of en- dometrial cancers and the implications for pathogenesis, classifica- tion and targeted therapies [ J ]. Cancer Control, 2009, 16 ( 1 ) : 8-13.
  • 2Cerezo L, Cardenes H, Michae 1H. Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implica- tions[J]. Clin Transl Oncol, 2006,8(4) :231-241.
  • 3Rinnert M, Hinz M, Buhtz P, et al. Synthesis and localization of trefoil factor family (TFFl) peptides in the human urinary tract and TFF2 excretion into the urine [J]. Cell Tissue Res, 2010,339 ( 3 ) : 639-647.
  • 4Zergeroglu S, Ozdemir HB, Ozel M, et al. The prognostic importance of proliferative activity and oestrogen receptor epression in stage I endometrial carcinomas [J]. J Obstet Gynaecol, 2006,26 (8) : 798-80l.
  • 5Chen CL, Hsieh FC, Lieblein JC, et al. Stat3 activation in human endometrial and cervical cancers [J]. Br J Cancer, 2007,96 ( 4 ) : 591-599.
  • 6Emami S, Le Floch N, Bruyneel E, et al. Induction of scattering and cellular invasion by trefoil peptides insrc-and RhoA -trans- formed kidney and colonic epithelial cells [J]. FASEBJ, 2001,15 (2) :351-36l.
  • 7Mhawech-Fauceglia P, Wang D, Wang D, et al. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade3 and grade 1 stage I endometrioid adenocarcinoma [J]. PLoS One, 2011 ,6(3) :eI8066.
  • 8Babyatsky M, Lin J, Yio X, et al. Trefoil factor-3 expression in human colon cancer liver metastasis [J ]. Clin Exp Metastasis, 2009,26(2) : 143-5l.
  • 9Gates EJ, Hirschfield L, Matthews RP, et al. Body mass index as a Prognostic factor in endometrioid adenocarcinoma of the endometrium[J]. J Nat! Med Assoc , 2006,98(11) :1814-1822.
  • 10Nan F, Lu Q, Zhou J, et al. Altered expression of DACHI and cyclin D1 in endometrial cancer [J ]. Cancer Bioi Ther, 2009, 8 (16) :1534-1539.

二级参考文献10

  • 1SUEMORI S, LYNCH-DEVANEV K, PODOLSKY D K. Identification and charcterization of rat intestinal trefoil factor: tissue- and cell sepecific member of the trefoil protein family [J]. ProcNatlAcad, 1991,88:11017-11021.
  • 2DHAR D K, WANG T C, TABARA H, et al. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis[J]. Clin Cancer Res, 2005, 11:6472 -6478.
  • 3KHOURY T, CHADHA K, JAVLE M, et al. Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma [J]. Int J Gastrointest Cancer, 2005,35(3):171-177.
  • 4LEUNG W K, YU J, CHAN F K L, et al. Expression of tre- foil peptidcs (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues[J]. Pathol, 2002,197 : 582-588.
  • 5CHAN V Y, CHAN M W, LEUNG W K, et al. Intestional trefoil factor promotes invasion in non-tumorigenic Rat-2 fibro- blast cell [J]. Regu Pept, 2005,127:87-94.
  • 6YAMACHIKA T, WERTHER J L, BIDUAN C, et al. Intes- tinal trefoil factor: a marker of poor prognosis in gastric carci- noma [J]. ClinCancer Res, 2002,8:1092 -1099.
  • 7NAGARAJAN KANNAN, JIAN KANG, XIANGJUN KONG, et al. Trefoil factor 3 is oncogenic and mediates anti- estrogen resistance in human mammary carcinoma[J]. Neo- plasia, 2010,12: 1041-1053.
  • 8KARLSSON P, COLE B F, PRICE K N, et al. The role of the number of uninvolved lymph nodes in predicting iocora- gional recurrence in breast cancer[J]. Clin Oncol, 2007,25: 2019- 2026.
  • 9DUNNWALD L K, ROSSING M A, LI C I, et al. Hormone receptor status, tumor characteristics and prognosis: a pro- spective cohort of breast cancer patients[J]. Breast Cancer Res, 2007,9:6-13.
  • 10路艳艳,田字彬,魏良洲,孔心涓,赵清喜,李玉军,孙显路.TFF3在胃癌、癌前病变及胃腺瘤中的表达及其与血管生成的关系[J].世界华人消化杂志,2009,17(36):3688-3692. 被引量:12

共引文献1

同被引文献74

  • 1谢立平,秦杰,郑祥毅,沈华峰,陈昭典,蔡松良,张志根,丁伟,任国平,王丽君,余心如.481例前列腺癌患者年龄与病理构成分析[J].中华男科学杂志,2005,11(6):428-430. 被引量:36
  • 2冯晓莉,主译.泌尿系统及男性生殖器官肿瘤病理学和遗传学.北京:人民卫生出版社,2006,257-263.
  • 3Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1) : 11-30.
  • 4Im S, Yoo C, Juug JH, et al. Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: Correlation with clinicopathological parameters and prognosis. Int J Med Sci, 2013, 10(2): 133-140.
  • 5Emami S, Rodrigues S, Rodrigue CM, et al. Trefoil factor family (TFF) peptidcs and cancer progression. Peptides, 2004, 25 ( 5 ) : 885-898.
  • 6Thuwajit P, Chawengrattanachot W, Thuwajit C, et al. Increased TFF1 trefoil protein expression in Opisthorehis viverrini-assoeiat- ed cholangiocarcinoma is important for invasive promotion. Hcpa- tol Res, 2007, 37(4) : 295-304.
  • 7Bougen NM, Amiry N, Yuan Y, et al. Trefoil factor 1 suppres- sion of E-CADHERIN enhances prostate carcinoma cell invasive- hess and metastasis. Cancer Lett, 2013, 332(1) : 19-29.
  • 8Abdou AG, Aiad HA, Sultan SM. pS2(TFFI) expression in prostate car- cinorra: Correlation with steroid receptor status. APMIS, 2008, 116(11) : 961-971.
  • 9Rickman DS, Chen YB, Banerjee S, et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia, 2010, 12(12) : 1031-1040.
  • 10Perry JK, Kannan N, Grandison PM, et al. Are trefoil factors oncogenie? Trends Endoerinol Metab, 2008, 19(2) : 74-81.

引证文献6

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部